Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer — Stella
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(164 sites)
United States
Research Site, Fountain Valley, California
Research Site, Los Alamitos, California
Research Site, Los Angeles, California
Research Site, Los Angeles, California
Research Site, Orange, California
Research Site, San Diego, California
Research Site, Santa Monica, California
Research Site, Walnut Creek, California
Research Site, New Haven, Connecticut
Research Site, Washington D.C., District of Columbia